Related Experiment Video
Updated: May 16, 2025
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Recommendations for essential medicines for multiple sclerosis in low-resource settings
Deanna Saylor1, Nick Rijke2, Jennifer McDonell3
1Department of Neurology, School of Medicine, Johns Hopkins University, Baltimore, MD, USA; Department of Medicine, University Teaching Hospital, Lusaka, Zambia.
Recommendations for essential multiple sclerosis (MS) treatments were developed for low-resource settings. The panel identified key disease-modifying therapies (DMTs) to improve access and outcomes for individuals with MS globally.
Area of Science:
- Neurology
- Immunology
- Public Health
Background:
- Multiple sclerosis (MS) is a central nervous system demyelinating disease causing disability in young adults.
- Access to disease-modifying therapies (DMTs) for MS is limited in low-resource settings.
Purpose of the Study:
- To establish minimum essential DMTs for MS treatment in low-resource environments.
- To ensure equitable access to effective MS therapies.
Main Methods:
- An international panel, including patients and healthcare professionals, was convened.
- Evidence for DMTs was reviewed using standardized GRADE protocols, considering benefits, harms, cost-effectiveness, and feasibility in low-resource contexts.
Main Results:
- For relapsing MS, recommended DMTs include ocrelizumab, cladribine, fingolimod, dimethyl fumarate, interferon beta, and glatiramer acetate.
- For progressive MS, recommended DMTs include rituximab, ocrelizumab, glatiramer acetate, fingolimod, and interferon beta.
Conclusions:
- Essential DMTs for MS in low-resource settings have been identified.
- Recommendations are based on comprehensive evidence and contextual factors, aiming to improve MS care globally.
More Related Videos
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022
Related Concept Videos
01:28Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:02Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:19Mesenchymal Stem Cells
01:22Drug Delivery: Miscellaneous Routes
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...